This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019.


SAN FRANCISCO — Quality of sleep significantly improved in patients with allergic rhinitis who were treated with the house dust mite (HDM) sublingual immunotherapy-tablet (12 SQ-HDM), according to a post hoc analysis presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) held February 22-25 in San Francisco.

In the original phase 3 trial, patients with moderate to severe HDM <a href="https://www.empr.com/home/mpr-first-report/aaaai-2019/gsp301-improves-ocular-symptoms-in-seasonal-allergic-rhinitis/" target="_blank" rel="noreferrer noopener" aria-label="In the original phase 3 trial, patients with moderate to severe HDM allergic rhinitis were treated for up to 1 year. The Rhinoconjunctivitis Quality of Life Questionnaire was used at baseline and throughout the trial. There were 3 sleep parameters that were scored from 0 to 6 (not troubled to extremely troubled): difficulty getting to sleep, wake up during the night, and lack of a good night's sleep. Scores allergic rhinitis were treated for up to 1 year. The Rhinoconjunctivitis Quality of Life Questionnaire was used at baseline and throughout the trial. There were 3 sleep parameters that were scored from 0 to 6 (not troubled to extremely troubled): difficulty getting to sleep, wake up during the night, and lack of a good night’s sleep. Scores <3 were considered “mildly affected” and scores ≥3 were considered “moderately/severely affected” for the purposes of this analysis.

Related Articles

Approximately 62% to 72% of the study population was considered moderately/severely affected at baseline, but only 7% to 10% remained in that category after treatment with the 12 SQ-HDM tablet. Improvements were observed across all the <a rel="noreferrer noopener" aria-label="Approximately 62% to 72% of the study population was considered moderately/severely affected at baseline, but only 7% to 10% remained in that category after treatment with the 12 SQ-HDM tablet. Improvements were observed across all the sleep parameters compared with placebo (lack of a good night's sleep: 12 SQ-HDM, 10.1% vs placebo, 27.5%; P <.001; wake up during the night: 12 SQ-HDM, 8.4% vs placebo, 23.0%; P sleep parameters compared with placebo (lack of a good night’s sleep: 12 SQ-HDM, 10.1% vs placebo, 27.5%; P<.001; wake up during the night: 12 SQ-HDM, 8.4% vs placebo, 23.0%; P<.001; and difficulty getting to sleep: 12 SQ-HDM, 7.3% vs placebo, 17.2%; P=.006).

Only 1% to 7% of participants who started in the mild category transitioned to the moderate/severe category at the end of treatment and there were no differences between the treatment and placebo groups.

The researchers concluded that patients who experienced poor sleep at the start of the trial experienced significant improvements in sleep quality with 12 SQ-HDM treatment.

Visit Monthly Prescribing Reference‘s conference section for continuous coverage of AAAAI 2019.

Reference

Jacobi H, Rehm D, Nolte H, Andersen KF, Demoly PM. Effect of house dust mite SLIT-table treatment on quality of sleep in allergic rhinitis patients. Presented at: Annual Meeting of the American Academic of Allergy, Asthma & Immunology; February 22-25, 2019; San Francisco, CA.